-+ 0.00%
-+ 0.00%
-+ 0.00%

Saniona gets FDA clearance for Phase 1 trial of SAN2465

PUBT·11/16/2026 07:06:04
Saniona gets FDA clearance for Phase 1 trial of SAN2465
  • Saniona received FDA clearance to begin a Phase 1 trial of SAN2465, its oral treatment candidate for major depressive disorder.
  • The healthy-volunteer study is expected to dose its first participant before year-end 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Saniona AB published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.